BioAsia 2015: Can India Move Beyond Its Low-cost Advantage?
This article was originally published in PharmAsia News
Drug discovery partnerships in India are at the cusp of big changes. Global innovators have moved away from considering India as a low-cost destination, instead looking beyond just outsourcing clinical development projects or in-licensing compounds. They are keen to forge long-term relationships with academia and also to look at model start-ups to spur a culture of innovation.
You may also be interested in...
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.